GSK
GSK
826 hedge funds and large institutions have $11.2B invested in GSK in 2020 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 248 increasing their positions, 336 reducing their positions, and 78 closing their positions.
21% more call options, than puts
Call options by funds: $81.6M | Put options by funds: $67.4M
0.13% less ownership
Funds ownership: 4.87% → 4.75% (-0.13%)
9% less first-time investments, than exits
New positions opened: 71 | Existing positions closed: 78
2% less funds holding
Funds holding: 840 → 826 (-14)
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
10% less capital invested
Capital invested by funds: $12.4B → $11.2B (-$1.21B)
26% less repeat investments, than reductions
Existing positions increased: 248 | Existing positions reduced: 336
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$139M |
| 2 |
Jane Street
New York
|
+$48.5M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$28M |
| 4 |
BCIM
Black Creek Investment Management
Toronto,
Ontario, Canada
|
+$27.6M |
| 5 |
D.E. Shaw & Co
New York
|
+$25.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$102M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$93.1M |
| 3 |
Renaissance Technologies
New York
|
-$89M |
| 4 |
Two Sigma Investments
New York
|
-$55.2M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$48.3M |
GSK Hedge Fund Activity: Q3 2020 in Review
826 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2020, worth a combined $11.2B — down 9.8% from $12.4B a quarter earlier.
Sellers outnumbered buyers: 78 funds closed out of GSK and 71 opened new positions — a net loss of 7 holders — while 336 trimmed existing stakes and 248 added.
The largest buyer was Dodge & Cox, adding an estimated $139M. The largest seller was Camber Capital Management, cutting an estimated $102M.
- 826 institutional investors held GSK (GSK) as of Q3 2020, down from 840 in Q2 2020.
- Funds reported $11.2B of GSK stock for Q3 2020, down 9.8% quarter-over-quarter.
- 71 funds opened new GSK positions in Q3 2020 and 78 closed out, a net change of -7 holders.
- The largest GSK buyer in Q3 2020 was Dodge & Cox, an estimated $139M added.
- The largest GSK seller in Q3 2020 was Camber Capital Management, an estimated $102M sold.
Based on aggregated 13F filings for Q3 2020.